Private Asset Management Inc. Has $480,000 Stock Position in Amgen, Inc. (NASDAQ:AMGN)

Private Asset Management Inc. trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 20.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,604 shares of the medical research company’s stock after selling 665 shares during the quarter. Private Asset Management Inc.’s holdings in Amgen were worth $480,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of AMGN. Carroll Financial Associates Inc. raised its stake in Amgen by 0.8% during the 2nd quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock valued at $1,370,000 after purchasing an additional 58 shares during the last quarter. Lincoln Capital Corp raised its stake in shares of Amgen by 0.3% in the 2nd quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock valued at $3,959,000 after buying an additional 58 shares in the last quarter. Slow Capital Inc. raised its stake in shares of Amgen by 0.4% in the 2nd quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock valued at $2,543,000 after buying an additional 58 shares in the last quarter. Nicholas Hoffman & Company LLC. raised its stake in shares of Amgen by 5.0% in the 2nd quarter. Nicholas Hoffman & Company LLC. now owns 1,207 shares of the medical research company’s stock valued at $222,000 after buying an additional 58 shares in the last quarter. Finally, CWM LLC raised its stake in shares of Amgen by 1.8% in the 2nd quarter. CWM LLC now owns 3,271 shares of the medical research company’s stock valued at $603,000 after buying an additional 59 shares in the last quarter. Institutional investors and hedge funds own 76.24% of the company’s stock.

In other Amgen news, Director R Sanders Williams sold 425 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the sale, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Cynthia M. Patton sold 13,426 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the sale, the senior vice president now directly owns 32,648 shares in the company, valued at approximately $6,793,069.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,851 shares of company stock worth $3,284,740. 0.25% of the stock is owned by insiders.

Shares of AMGN traded up $2.94 during trading hours on Thursday, hitting $192.15. The stock had a trading volume of 476,140 shares, compared to its average volume of 2,683,042. The company’s fifty day moving average is $200.80 and its two-hundred day moving average is $185.99. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $211.90. The stock has a market capitalization of $116.05 billion, a price-to-earnings ratio of 13.34, a P/E/G ratio of 2.52 and a beta of 1.11.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the firm earned $3.83 EPS. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year. Equities analysts predict that Amgen, Inc. will post 14.3 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 6th. Stockholders of record on Thursday, August 15th were issued a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.02%. The ex-dividend date was Wednesday, August 14th. Amgen’s payout ratio is 40.28%.

A number of brokerages have recently issued reports on AMGN. William Blair restated a “hold” rating on shares of Amgen in a research note on Friday, August 30th. Cantor Fitzgerald set a $230.00 price objective on shares of Amgen and gave the company a “hold” rating in a research note on Monday. Citigroup restated a “buy” rating on shares of Amgen in a research note on Monday, August 12th. BMO Capital Markets set a $240.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Monday. Finally, Royal Bank of Canada restated a “hold” rating on shares of Amgen in a research note on Monday. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. Amgen presently has an average rating of “Hold” and a consensus price target of $217.41.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is insider trading?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.